

Ostomy Care Continence Care Wound & Skin Care Interventional Urology

# Coloplast – transactions in connection with share buy-back programme

As mentioned in Announcement no. 02/2020 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.

The programme will commence on 24 February 2020 and is expected to end by 24 August 2020.

The share buyback programme is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR.

Number of shares Date Average purchase Transaction value, price, DKK DKK 300 20 July 2020 1,092.67 327,801 300 1,094.90 21 July 2020 328,470 22 July 2020 200 1,078.22 215,644 23 July 2020 300 1,083.13 324,939 24 July 2020 400 1,061.74 424,696 Accumulated until now 468,802 986.04 462,255,671 under the programme

The following transactions have been executed during the period 20 – 24 July 2020:

Henceforth, Coloplast owns 3,291,317 treasury B shares of DKK 1 equal to 1.52% of the company's total share capital.

An overview showing the transaction data for the period 20 – 24 July 2020 is enclosed.

Kind regards, Investor Relations Coloplast A/S Tel. +45 4911 1800 Announcement 27 July 2020



Ostomy Care Continence Care Wound & Skin Care Interventional Urology

## Our mission

Making life easier for people with intimate healthcare needs

#### Our values

Closeness... to better understand Passion... to make a difference Respect and responsibility... to guide us

#### Our vision

Setting the global standard for listening and responding

## For further information, please contact

## Investors and analysts

Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111

Ellen Bjurgert Vice President, Investor Relations Tel. +45 4911 1800 /+45 4911 3376 Email: dkebj@coloplast.com

Rasmus Sørensen Sr. Manager, Investor Relations Tel. +45 4911 1800 /+45 4911 1786 Email: dkraso@coloplast.com

## Press and the media

Lina Danstrup Sr. Media Relations Manager Tel. 4911 2607 Email: dklina@coloplast.com

## **Address**

Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Company reg. (CVR) no. 69749917

## Website

www.coloplast.com

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,000 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2020-07. All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark

Investor Relations Tel. +45 4911 1800 Fax +45 4911 1555 www.coloplast.com Comp. reg. (CVR). 69749917